Skip to main content

4 Result(s)

within Sonja Kallendrusch Remove this filter

and
Your search also matched 2 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you. results, e.g.

Optimized polyethylenimine (PEI)-based nanoparticles for siRNA delivery, analyzed in vitro and in an ex vivo tumor tissue slice culture model

Include preview-only content

  1. Article

    Open Access

    Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers

    T-cell retargeting to eliminate CEACAM5-expressing cancer cells via CEACAM5xCD3 bispecific antibodies (BsAbs) showed limited clinical activity so far, mostly due to insufficient T-cell activation, dose-limitin...

    Anja Seckinger, Sara Majocchi, Valéry Moine… in Journal of Hematology & Oncology (2023)

    Download PDF (7748 KB) View Article

  2. Article

    Open Access

    A tumor microenvironment-based prognostic index for osteosarcoma

    The tumor microenvironment (TME) has a central role in the oncogenesis of osteosarcomas. The composition of the TME is essential for the interaction between tumor and immune cells. The aim of this study was to...

    Changwu Wu, Siming Gong, Yingjuan Duan, Chao Deng… in Journal of Biomedical Science (2023)

    Download PDF (11480 KB) View Article

  3. Article

    Open Access

    Human tissue cultures of lung cancer predict patient susceptibility to immune-checkpoint inhibition

    Despite novel immunotherapies being approved and established for the treatment of non-small cell lung cancer (NSCLC), ex vivo models predicting individual patients’ responses to immunotherapies are missing. Es...

    David Junk, Sebastian Krämer, Johannes Broschewitz, Hennig Laura… in Cell Death Discovery (2021)

    Download PDF (3576 KB) View Article

  4. Article

    Open Access

    The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment

    Glioblastoma is the most common and aggressive brain tumour in adults with a median overall survival of only 14 months after standard therapy with radiation therapy (IR) and temozolomide (TMZ). In a novel mult...

    Ina Patties, Sonja Kallendrusch, Lisa Böhme… in Journal of Experimental & Clinical Cancer … (2019)

    Download PDF (3949 KB) View Article